proxyvotesnow.com

Home › Companies › SUMMIT THERAPEUTICS INC. › 2024-2025

SUMMIT THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and SUMMIT THERAPEUTICS INC.’s Form 8-K, filed June 17, 2025 (Item 5.07 on EDGAR). Page generated November 1, 2026.

  • 11Ballot items
  • 226Asset managers
  • 2,643Fund votes
  • June 12, 2025Meeting date

Results at a glance

Meeting of June 12, 2025: 11 items on SUMMIT THERAPEUTICS INC.’s Form 8-K, filed June 17, 2025: 11 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SUMMIT THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by SUMMIT THERAPEUTICS INC.

These tallies are SUMMIT THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SUMMIT THERAPEUTICS INC. — official shareholder meeting results, meeting held June 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Robert W. Duggan 613,045,226---- 26,69229,651,787 99.9%Not verified—
Elect Director: Mahkam Zanganeh 613,581,910---- 37,54629,651,787 99.9%Not verified—
Elect Director: Manmeet Soni 611,431,814---- 52,32629,651,787 99.9%Not verified—
Elect Director: Kenneth A. Clark 605,079,891---- 51,55829,651,787 99.9%Not verified—
Elect Director: Robert Booth 623,298,472---- 55,31929,651,787 99.9%Not verified—
Elect Director: Alessandra Cesano 617,638,155---- 54,44329,651,787 99.9%Not verified—
Elect Director: Yu (Michelle) Xia 610,437,122---- 54,39629,651,787 99.9%Not verified—
Elect Director: Mostafa Ronaghi 620,904,380---- 54,32429,651,787 99.9%Not verified—
Elect Director: Jeff Huber 623,664,686---- 53,33029,651,787 99.9%Not verified—
Ratification of the appointment of PricewaterhouseCoopers LLP 653,328,708195,007233,629 ---- 99.9%Not verified—
Advisory vote to approve the compensation of named executive officers 607,320,35316,607,648177,556 --29,651,787 97%Not verified—

Source: SUMMIT THERAPEUTICS INC., Form 8-K, filed with the SEC on June 17, 2025 — read the filing on EDGAR.

How asset managers voted at the SUMMIT THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 226 asset managers that disclosed a SUMMIT THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Alessandra Cesano

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 617,638,155WITHHELD: 54,443
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Alessandra Cesano

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Alessandra Cesano”): 617,638,155 for, 54,443 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 9,918,109 for, 4,534,823 against, 3,840 abstained, 72 not voted.

FORAGAINST
FOR: 9,918,109AGAINST: 4,534,823ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Alessandra Cesano” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price4,400,6700 00For
Vanguard8033,701,082 00Against
Fidelity1,300,3950 00For
Charles Schwab1,250,3410 00For
Aberdeen1,200,8100 00For
BlackRock0725,530 00Against
State Street228,82865 00For
Lincoln Financial223,7360 00For
Putnam169,6730 00For
Equitable100,62714,710 00Mixed
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock87,5030 00For
Calamos72,8440 00For
Direxion Shares ETF Trust70,4170 00For
OPTIMUM FUND TRUST67,4410 00For
Principal Exchange-Traded Funds61,7220 00For
AQR60,8150 00For
ProShares50,7500 00For
TIAA47,7900 00For
AIG/SunAmerica47,2620 00For
Northern Trust42,5630 00For
JPMorgan31,8020 00For
Pacific Life030,452 00Against
Brighthouse24,7220 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

2. Elect Director: Jeff Huber

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 623,664,686WITHHELD: 53,330
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Jeff Huber

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jeff Huber”): 623,664,686 for, 53,330 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 14,429,752 for, 23,180 against, 3,840 abstained, 72 not voted.

FOR
FOR: 14,429,752AGAINST: 23,180ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Jeff Huber” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price4,400,6700 00For
Vanguard3,701,117768 00For
Fidelity1,300,3950 00For
Charles Schwab1,250,3410 00For
Aberdeen1,200,8100 00For
BlackRock725,5300 00For
State Street228,82865 00For
Lincoln Financial223,7360 00For
Putnam169,6730 00For
Equitable115,3370 00For
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock87,5030 00For
Calamos72,8440 00For
Direxion Shares ETF Trust70,4170 00For
OPTIMUM FUND TRUST67,4410 00For
Principal Exchange-Traded Funds61,7220 00For
AQR60,8150 00For
ProShares50,7500 00For
TIAA47,7900 00For
AIG/SunAmerica47,2620 00For
Northern Trust42,5630 00For
JPMorgan31,8020 00For
Pacific Life30,4520 00For
Brighthouse24,7220 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

3. Elect Director: Kenneth A. Clark

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 605,079,891WITHHELD: 51,558
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Kenneth A. Clark

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kenneth A. Clark”): 605,079,891 for, 51,558 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 4,750,781 for, 9,702,150 against, 3,840 abstained, 72 not voted.

FORAGAINST
FOR: 4,750,781AGAINST: 9,702,150ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Kenneth A. Clark” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price04,400,670 00Against
Vanguard3,701,117768 00For
Fidelity66,3721,234,023 00Mixed
Charles Schwab4531,249,888 00Against
Aberdeen01,200,810 00Against
BlackRock422,891302,639 00Mixed
State Street642228,251 00Against
Lincoln Financial0223,736 00Against
Putnam169,6730 00For
Equitable14,710100,627 00Mixed
Russell Investments0106,900 00Against
Tema ETF Trust99,2150 00For
John Hancock087,503 00Against
Calamos72,8440 00For
Direxion Shares ETF Trust070,417 00Against
OPTIMUM FUND TRUST067,441 00Against
Principal Exchange-Traded Funds061,722 00Against
AQR060,815 00Against
ProShares050,750 00Against
TIAA47,7900 00For
AIG/SunAmerica047,262 00Against
Northern Trust42,5630 00For
JPMorgan031,802 00Against
Pacific Life30,4520 00For
Brighthouse024,722 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

4. Elect Director: Mahkam Zanganeh

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 613,581,910WITHHELD: 37,546
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Mahkam Zanganeh

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mahkam Zanganeh”): 613,581,910 for, 37,546 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 9,318,420 for, 5,134,512 against, 3,840 abstained, 72 not voted.

FORAGAINST
FOR: 9,318,420AGAINST: 5,134,512ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Mahkam Zanganeh” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price04,400,670 00Against
Vanguard3,701,8850 00For
Fidelity1,300,3950 00For
Charles Schwab1,250,3410 00For
Aberdeen1,200,8100 00For
BlackRock725,5300 00For
State Street228,605288 00For
Lincoln Financial67,900155,836 00Mixed
Putnam169,6730 00For
Equitable107,4407,897 00Mixed
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock087,503 00Against
Calamos72,8440 00For
Direxion Shares ETF Trust070,417 00Against
OPTIMUM FUND TRUST067,441 00Against
Principal Exchange-Traded Funds061,722 00Against
AQR060,815 00Against
ProShares050,750 00Against
TIAA47,7900 00For
AIG/SunAmerica047,262 00Against
Northern Trust42,5630 00For
JPMorgan031,802 00Against
Pacific Life30,4520 00For
Brighthouse024,722 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

5. Elect Director: Manmeet Soni

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 611,431,814WITHHELD: 52,326
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Manmeet S. Soni

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Manmeet Soni”): 611,431,814 for, 52,326 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 8,963,239 for, 5,489,693 against, 3,840 abstained, 72 not voted.

FORAGAINST
FOR: 8,963,239AGAINST: 5,489,693ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Manmeet S. Soni” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price04,400,670 00Against
Vanguard3,701,117768 00For
Fidelity1,300,3950 00For
Charles Schwab1,250,201139 00For
Aberdeen1,200,8100 00For
BlackRock725,5300 00For
State Street642228,251 00Against
Lincoln Financial0223,736 00Against
Putnam169,6730 00For
Equitable107,4407,897 00Mixed
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock087,503 00Against
Calamos72,8440 00For
Direxion Shares ETF Trust070,417 00Against
OPTIMUM FUND TRUST067,441 00Against
Principal Exchange-Traded Funds061,722 00Against
AQR060,815 00Against
ProShares050,750 00Against
TIAA47,7900 00For
AIG/SunAmerica047,262 00Against
Northern Trust42,5630 00For
JPMorgan031,802 00Against
Pacific Life30,4520 00For
Brighthouse024,722 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

6. Elect Director: Mostafa Ronaghi

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 620,904,380WITHHELD: 54,324
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Mostafa Ronaghi

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Mostafa Ronaghi”): 620,904,380 for, 54,324 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 13,195,729 for, 1,257,203 against, 3,840 abstained, 72 not voted.

FOR
FOR: 13,195,729AGAINST: 1,257,203ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Mostafa Ronaghi” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price4,400,6700 00For
Vanguard3,701,117768 00For
Fidelity66,3721,234,023 00Mixed
Charles Schwab1,250,3410 00For
Aberdeen1,200,8100 00For
BlackRock725,5300 00For
State Street228,82865 00For
Lincoln Financial223,7360 00For
Putnam169,6730 00For
Equitable115,3370 00For
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock87,5030 00For
Calamos72,8440 00For
Direxion Shares ETF Trust70,4170 00For
OPTIMUM FUND TRUST67,4410 00For
Principal Exchange-Traded Funds61,7220 00For
AQR60,8150 00For
ProShares50,7500 00For
TIAA47,7900 00For
AIG/SunAmerica47,2620 00For
Northern Trust42,5630 00For
JPMorgan31,8020 00For
Pacific Life30,4520 00For
Brighthouse24,7220 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

7. Elect Director: Robert Booth

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 623,298,472WITHHELD: 55,319
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Robert Booth

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert Booth”): 623,298,472 for, 55,319 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 14,427,092 for, 25,840 against, 3,840 abstained, 72 not voted.

FOR
FOR: 14,427,092AGAINST: 25,840ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Robert Booth” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price4,400,6700 00For
Vanguard3,701,117768 00For
Fidelity1,300,3950 00For
Charles Schwab1,250,3410 00For
Aberdeen1,200,8100 00For
BlackRock725,5300 00For
State Street228,82865 00For
Lincoln Financial223,7360 00For
Putnam169,6730 00For
Equitable115,3370 00For
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock87,5030 00For
Calamos72,8440 00For
Direxion Shares ETF Trust70,4170 00For
OPTIMUM FUND TRUST67,4410 00For
Principal Exchange-Traded Funds61,7220 00For
AQR60,8150 00For
ProShares50,7500 00For
TIAA47,7900 00For
AIG/SunAmerica47,2620 00For
Northern Trust42,5630 00For
JPMorgan31,8020 00For
Pacific Life30,4520 00For
Brighthouse24,7220 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

8. Elect Director: Robert W. Duggan

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 613,045,226WITHHELD: 26,692
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Robert W. Duggan

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Robert W. Duggan”): 613,045,226 for, 26,692 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 9,301,747 for, 5,151,185 against, 3,840 abstained, 72 not voted.

FORAGAINST
FOR: 9,301,747AGAINST: 5,151,185ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Robert W. Duggan” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price04,400,670 00Against
Vanguard3,701,8850 00For
Fidelity1,300,3950 00For
Charles Schwab1,250,3410 00For
Aberdeen1,200,8100 00For
BlackRock725,5300 00For
State Street228,605288 00For
Lincoln Financial67,900155,836 00Mixed
Putnam169,6730 00For
Equitable107,4407,897 00Mixed
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock087,503 00Against
Calamos72,8440 00For
Direxion Shares ETF Trust070,417 00Against
OPTIMUM FUND TRUST067,441 00Against
Principal Exchange-Traded Funds061,722 00Against
AQR060,815 00Against
ProShares050,750 00Against
TIAA47,7900 00For
AIG/SunAmerica047,262 00Against
Northern Trust42,5630 00For
JPMorgan031,802 00Against
Pacific Life30,4520 00For
Brighthouse024,722 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

9. Elect Director: Yu (Michelle) Xia

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 610,437,122WITHHELD: 54,396
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Yu (Michelle) Xia

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Elect Director: Yu (Michelle) Xia”): 610,437,122 for, 54,396 withheld, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 7,800,244 for, 6,652,688 against, 3,840 abstained, 72 not voted.

FORAGAINST
FOR: 7,800,244AGAINST: 6,652,688ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “ELECTION OF DIRECTORS: Yu (Michelle) Xia” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price04,400,670 00Against
Vanguard3,701,8850 00For
Fidelity1,300,3950 00For
Charles Schwab1,250,3410 00For
Aberdeen01,200,810 00Against
BlackRock725,5300 00For
State Street642228,251 00Against
Lincoln Financial0223,736 00Against
Putnam169,6730 00For
Equitable107,4407,897 00Mixed
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock087,503 00Against
Calamos72,8440 00For
Direxion Shares ETF Trust070,417 00Against
OPTIMUM FUND TRUST067,441 00Against
Principal Exchange-Traded Funds061,722 00Against
AQR060,815 00Against
ProShares050,750 00Against
TIAA47,7900 00For
AIG/SunAmerica047,262 00Against
Northern Trust42,5630 00For
JPMorgan031,802 00Against
Pacific Life30,4520 00For
Brighthouse024,722 3,8400Mixed

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

10. Advisory vote to approve the compensation of named executive officers

Outcome not verifiedFund totals may overlapCOMPENSATIONReported outcome: Not verified

Combines 11 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 607,320,353AGAINST: 16,607,648
Details: description as filed, official tally, votes by 226 asset managers

Description as filed by funds: Approval, by a non-binding advisory vote, of the compensation of our named executive officers.

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Advisory vote to approve the compensation of named executive officers”): 607,320,353 for, 16,607,648 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price04,400,670 00Against
Vanguard3,701,117768 00For
Fidelity66,3721,234,023 00Mixed
Charles Schwab1,250,3410 00For
Aberdeen01,200,810 00Against
BlackRock725,5300 00For
State Street228,605288 00For
Lincoln Financial67,900155,836 00Mixed
Putnam0169,673 00Against
Equitable14,710100,627 00Mixed
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock087,503 00Against
Calamos72,8440 00For
Direxion Shares ETF Trust070,417 00Against
OPTIMUM FUND TRUST067,441 00Against
Principal Exchange-Traded Funds061,722 00Against
AQR060,815 00Against
ProShares050,750 00Against
TIAA47,7900 00For
AIG/SunAmerica047,262 00Against
Northern Trust42,5630 00For
JPMorgan031,802 00Against
Pacific Life30,4520 00For
Brighthouse024,722 3,8400Mixed

Fund voting reports, all 58 managers: 6,551,445 for, 7,892,269 against, 3,840 abstained, 72 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 182 asset managers voting on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price05,375,687 00Against
Fidelity02,748,279 00Against
PICTET ASSET MANAGEMENT SA02,324,786 00Against
Charles Schwab1,251,5060 00For
State Street1,238,5766,975 00For
Aberdeen01,200,810 00Against
BlackRock1,107,27633,892 00For
ROCKLAND TRUST CO800,0000 00For
Rock Springs Capital Management LP0570,994 00Against
ADAGE CAPITAL PARTNERS GP, L.L.C.464,1350 00For
Northern Trust430,0490 00For
JPMorgan0271,962 00Against
Putnam0246,973 00Against
Point720235,502 00Against
Ensign Peak Advisors, Inc220,7330 00For
Allianz0211,625 00Against
Russell Investments208,0080 00For
Citadel189,5070 00For
BANK OF AMERICA NA184,6400 00For
BANK OF MONTREAL /CAN/856179,414 00Against
PRINCIPAL GLOBAL INVESTORS0171,289 00Against
Vanguard162,9694,531 00For
MELLON INVESTMENTS Corp0148,574 00Against
BALYASNY ASSET MANAGEMENT L.P.123,4650 00For
GRIFFIN ASSET MANAGEMENT, INC.0118,442 00Against

Institutional-manager reports, all 182 managers: 7,035,929 for, 14,821,431 against, 23 abstained, 262 not voted. Showing the 25 largest; see all in the interactive database.

11. Ratification of the appointment of PricewaterhouseCoopers LLP

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 653,328,708AGAINST: 195,007
Details: description as filed, official tally, votes by 58 asset managers

Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2025.

SUMMIT THERAPEUTICS INC.’s own tally for this item (“Ratification of the appointment of PricewaterhouseCoopers LLP”): 653,328,708 for, 195,007 against, per its Form 8-K filed June 17, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 58 asset managers below reported 14,449,105 for, 478 against, 3,840 abstained, 72 not voted.

FOR
FOR: 14,449,105AGAINST: 478ABSTAIN: 3,840NOT VOTED: 72
Largest asset managers voting on “Ratification of the appointment of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm” at SUMMIT THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price4,400,6700 00For
Vanguard3,701,8850 00For
Fidelity1,300,3950 00For
Charles Schwab1,250,3410 00For
Aberdeen1,200,8100 00For
BlackRock725,5300 00For
State Street228,8930 00For
Lincoln Financial223,7360 00For
Putnam169,6730 00For
Equitable115,3370 00For
Russell Investments106,9000 00For
Tema ETF Trust99,2150 00For
John Hancock87,5030 00For
Calamos72,8440 00For
Direxion Shares ETF Trust70,4170 00For
OPTIMUM FUND TRUST67,4410 00For
Principal Exchange-Traded Funds61,7220 00For
AQR60,8150 00For
ProShares50,7500 00For
TIAA47,7900 00For
AIG/SunAmerica47,2620 00For
Northern Trust42,5630 00For
JPMorgan31,8020 00For
Pacific Life30,4520 00For
Brighthouse24,7220 3,8400Mixed

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

Largest SUMMIT THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 741,609,390 shares outstanding at the time of that meeting.

Fund voting reports: top SUMMIT THERAPEUTICS INC. shareholders by shares voted on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1T. Rowe Price 0.59%
2Vanguard 0.50%
3Fidelity 0.18%
4Charles Schwab 0.17%
5Aberdeen 0.16%
6BlackRock 0.10%
7State Street 0.03%
8Lincoln Financial 0.03%
9Putnam 0.02%
10Equitable 0.02%
Institutional-manager reports: top SUMMIT THERAPEUTICS INC. shareholders by shares voted on “Approval, by a non-binding advisory vote, of the compensation of our named executive officers.”, 2024-2025
#Asset manager % of shares outstanding
1T. Rowe Price 0.72%
2Fidelity 0.37%
3PICTET ASSET MANAGEMENT SA 0.31%
4Charles Schwab 0.17%
5State Street 0.17%
6Aberdeen 0.16%
7BlackRock 0.15%
8ROCKLAND TRUST CO 0.11%
9Rock Springs Capital Management LP 0.08%
10ADAGE CAPITAL PARTNERS GP, L.L.C. 0.06%

Reported SUMMIT THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

SUMMIT THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
Robert W. Duggan 74.93% DEF14A
Mahkam Zanganeh 4.82% DEF14A
Yu (Michelle) Xia 4.25% DEF14A
Vanguard Group 1.57% 13F
FMR (Fidelity) 1.26% 13F
BlackRock 1.13% 13F
T. Rowe Price 0.88% 13F
State Street 0.65% 13F
Geode Capital 0.44% 13F
Manmeet Soni 0.41% DEF14A

Percentages above are of 741,609,390 shares outstanding, as reported by SUMMIT THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUMMIT THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 1, 2026; a live search always shows the current data.

At SUMMIT THERAPEUTICS INC.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 226 asset managers reported how they voted on 11 ballot items in their SEC Form N-PX filings, covering 2,643 separate fund positions. On the most widely held item on that ballot — Approval, by a non-binding advisory vote, of the compensation of our named executive officers. — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUMMIT THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2025.

SUMMIT THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.